When you're a STAT+ subscriber, you get discounts on our STAT Reports and events, free access to premium data tools like our Obesity Drug Tracker, as well as in-depth daily coverage and analysis of the life sciences.
Exclusive to STAT+ subscribers, STAT will be hosting a workspace just steps away from the heart of Union Square during the week of the J.P. Morgan Healthcare Conference. The perfect place to work or take meetings during this bustling, biggest week in biotech – free coffee, snacks, and wifi will be provided. Subscribers are also invited to bring a guest!
Join STAT's biotech team in San Francisco as they take the stage to help you digest all the biggest stories from the year's biggest investor conference on January 8.Learn more.
March 21, 2024 | 345 Park Ave S, New York + Virtual
New initiatives and all sorts of tools and technologies aim to improve the patient experience. Pharma and biotech companies claim to put the patient at the center of what they do. So, too, do research organizations. But what does focusing on patients really mean? How should it shape an R&D effort? And how should patient voices shape regulation, commerce, and the practice of medicine? We'll look at these questions broadly in biotech and health tech, gathering top experts, CEOs, and, of course, patients to come up with real, deliverable answers about how to make sure that science is benefitting the people who desperately need it.
Get up to 50% off with Early Bird until January 14th.
Relive this year's J.P. Morgan Healthcare Conference with the STAT reporters who attended. Get a full rundown of the deals, data, and scuttlebutt and come away with the ideas and water-cooler chatter you need for the year ahead.
Rare diseases pose significant challenges for the 25-30 million individuals in the U.S. living with one of over 7,000 known rare diseases. It is clear that those with rare diseases need more attention. Download this e-book to explore advocacy for increased attention to rare diseases, the need for improved diagnostics, treatment affordability, research efficiency, and equitable access to care through the latest advances in research and therapeutics for rare diseases.
No comments